Toby Talbot
2 Papers
Toby Talbot is an academic researcher. The author has contributed to research in topics: Placebo & Vemurafenib. The author has an hindex of 2, co-authored 2 publications.
Chat about Author
Papers
Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
Michele Maio,Karl D. Lewis,Lev V. Demidov,Mario Mandalà,Igor Bondarenko,Paolo A. Ascierto,Christopher Herbert,Andrzej Mackiewicz,Piotr Rutkowski,Alexander Guminski,Grant R. Goodman,B. Simmons,Chenglin Ye,Yibing Yan,Dirk Schadendorf,Gabriela Cinat,Luis Fein,Michael C. Brown,Andrew Haydon,Adnan Khattak,Catriona M. McNeil,Phillip Parente,Jeremy Power,Rachel Roberts-Thomson,Shahneen Sandhu,Craig Underhill,Suresh Varma,Thomas Berger,Ahmad Awada,Nathalie Blockx,Veronique Buyse,Jeroen Mebis,Fabio Franke,Sergio J Azevedo,Nicolas Silva Lazaretti,Rahima Jamal,Catalin Mihalcioiu,Teresa M. Petrella,Kerry J. Savage,Xinni Song,Ralph Wong,Nina Dabelic,Stjepko Plestina,Zeljko Vojnovic,Petr Arenberger,Ivo Kocak,Ivana Krajsová,Eugen Kubala,Bohuslav Melichar,Yvetta Vantuchova,Kadri Putnik,Brigitte Dréno,Caroline Dutriaux,Jean-Jacques Grob,Pascal Joly,Jean-Philippe Lacour,Nicolas Meyer,Laurent Mortier,Luc Thomas,Michael Fluck,Thilo Gambichler,Jessica C. Hassel,Axel Hauschild,Paul Donnellan,John McCaffrey,Derek G. Power,Samuel Ariad,Gil Bar-Sela,Daniel Hendler,Ilan G. Ron,Jacob Schachter,Paolo A. Ascierto,Alfredo Berruti,Luca Bianchi,Vanna Chiarion Sileni,Francesco Cognetti,Riccardo Danielli,Anna Maria Di Giacomo,Luca Gianni,Aron Goldhirsch,Michele Guida,Paolo Marchetti,Paola Queirolo,Armando Santoro,Ellen Kapiteijn,Paula Ferreira,Georgy Gafton,Yulia Makarova,Zoran Andric,Nada Babovic,Darjana Jovanovic,Lidija Sekulovic,Graham Lawrence Cohen,Lydia Dreosti,Daniel A. Vorobiof,Maria Teresa Curiel Garcia,Roberto Diaz Beveridge,Margarita Majem Tarruella,Ivan Marquez Rodas,Jose-M Puliats Rodriguez,Antonio Rueda Dominguez,Marianne Maroti,Karin Papworth,Olivier Michielin,Ewan Brown,Pippa Corrie,Mark Harries,Satish Kumar,Agustin Martin-Clavijo,Mark R. Middleton,Poulam M. Patel,Toby Talbot,Sanjiv S. Agarwala,Paul B. Chapman,Robert M. Conry,Gary Doolittle,Tara C. Gangadhar,Sigrun Hallmeyer,Omid Hamid,Leonel Hernandez-Aya,Douglas B. Johnson,Frederic Kass,Tatjana Kolevska,Scott Lunin,April K.S. Salama,Branimir I. Sikic,Bradley Somer,David R. Spigel,Eric D. Whitman +128 more
TL;DR: The BRIM8 study evaluated adjuvant vemurafenib monotherapy in patients with resected, BRAFV600 mutation-positive melanoma and the result was not significant because of the prespecified hierarchical prerequisite for the primary disease-free survival analysis of cohort 2 to show a significant health benefit.
190
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial.
Martin Schuler,Martin Schuler,Jingzhen Yang,Kwan Park,Jeong-Ho Kim,J. Bennouna,Y.-M. Chen,C. Chouaid,F. De Marinis,J.-F. Feng,F. Grossi,D-W. Kim,X. Liu,Shaoyong Lu,J. Strausz,Y. Vinnyk,R. Wiewrodt,C. Zhou,B. Wang,V. K. Chand,D. Planchard,Sai-Hong Ignatius Ou,David Planchard,Keunchil Park,Martin Schuler,James Chih-Hsin Yang,Vikram K. Chand,Klaus Rohr,Claudia Bagnes,Claudio Martin,Gonzalo Recondo,J. J. Zarba,Cesar Blajman,Martín Richardet,Sue-Anne McLachlan,Phillip Parente,Craig Underhill,Catherine Crombie,Paul N. Mainwaring,Richard Greil,Yves Humblet,Frédérique Bustin,Luciano Carestia,Danny Galdermans,Marc Lambrechts,Laetitia Delval,Piet Vercauter,Caicun Zhou,Jin Wang,Cheng Huang,Xiaoyan Lin,Yi-Long Wu,Xiaoqing Liu,Ying Cheng,Shukui Qin,Jifeng Feng,Jianjin Huang,Yiping Zhang,Shun Lu,Manuela Zereu,Bernardo Garicochea,Cyntia Albuquerque Zadra,Henrik Riska,Tuomo Alanko,Jacques Cadranel,Christos Chouaid,Gérard Zalcman,Denis Moro Sibilot,Maurice Perol,Jaafar Bennouna,Pierre Fournel,Radj Gervais,Maciej Rotarski,Bruno Coudert,Michael Thomas,Thomas Wehler,Martin Faehling,Ulrich Keilholz,E. Laack,Joachim von Pawel,Rudolf M. Huber,Nicolas Dickgreber,Rainer Wiewrodt,Zsuzsanna Mark,Sandor Tehenes,Janos Strausz,Veronika Sarosi,Kumar Prabhash,Minish Jain,Srinivasan Venkatesan,Lalit Sharma,Hemant Dadhich,Rajnish Vasant Nagarkar,Amir Onn,Maya Gottfried,Solomon Stemmer,Maria Rita Migliorino,Francesco Grossi,P. Bidoli,Alessandra Bearz,Cesare Gridelli,Carlo Milandri,Marco Platania,Giovanni Luca Ceresoli,Giorgio Cruciani,Francisco Gutierrez Delgado,José Luis Gonzalez Perez,Gabriela Alvarado Luna,Othon Padilla Baca,Joachim G.J.V. Aerts,J.A. Stigt,A-M.C. Dingemans,G.J.M. Herder,S. J. M. Gans,Jorge Fernando Salas Sánchez,Renzo Luzgardo Alvarez Barreda,Wilbert Rodriguez Pantigoso,Osbert Luis Mejia Palomino,Piotr Jaskiewicz,Andrzej Kazarnowicz,Piotr Serwatowski,Aleksandra Szczesna,Jacek Jassem,Vladimir Lubennikov,Nina Karaseva,Sergey Orlov,Yuri Ragulin,Pilar Garrido,José Luis González Larriba,Carlos Camps,Rosario Garcia Campelo,Pilar Lianes,Manuel Cobo,Enriqueta Felip,Dong Wan Kim,Sang-We Kim,Joo Hang Kim,Ji-Youn Han,Young-Chul Kim,Chih-Hsin Yang,Te Chun Hsia,Yuh Min Chen,Ying-Huang Tsai,Gee-Chen Chang,Thomas Chang-Yao Tsao,Wu Chou Su,Ming-Shyan Huang,C. L. Ho,Ruey-Kuen Hsieh,Yuriy Vinnyk,Oleksandr Popovych,Olga Ponomarova,Igor Bondarenko,Iryna Polishchuk,Riyaz Shah,Sanka Mitra,Sanjaykumar Popat,James Spicer,Elizabeth Toy,Toby Talbot,Emma Brown,Sunil Upadhyay,Yvonne Summers,Jayne Gurtler,Luis Meza,John Thropay +165 more
TL;DR: In this prospective phase III trial, afatinib combined with paclitaxel improved progression-free survival and objective response, compared with single-agent chemotherapy, in patients with NSCLC who were clinically enriched for ErbB dependency having failed platinum-based chemotherapy.
129